The brain busting side-effects of Ozempic-like fat jabs revealed – ‘slashing risk of silent killers'
New research suggests these so-called ' skinny pens ' may also supercharge your brain and protect against two killer diseases.
3
3
Scientists from Taiwan found that these fat-busting jabs may help lower the chances of developing dementia and stroke.
People with type 2 diabetes and obesity who took the drugs were also less likely to die early, the researchers discovered.
While everyone knows these drugs, like Wegovy and Mounjaro, help with weight and blood sugar control, experts say some of their other benefits are still a bit of a mystery.
For the study, published in JAMA Network Open, experts from Chang Gung Memorial Hospita l looked at data from 60,000 people around the world.
The average age was 58 and all had type 2 diabetes and obesity.
About half of the group were given drugs called GLP1-RAs. These include semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) to manage their diabetes.
Semaglutide is also the main ingredient in the popular diabetes drug Ozempic, which is licensed for diabetes, while Wegovy is licensed for weight loss.
These drugs work by lowering appetite, slowing digestion, reducing sugar production in the liver, and helping the body make more insulin when needed.
The other half of the participants were on different diabetes medications.
After following everyone for seven years, the researchers found the people using GLP1-RAs had a 37 percent lower risk of dementia and were 19 percent less likely to have a stroke.
Weight Loss Jabs - Pros vs Cons
These conditions are often called silent killers because they can creep up without obvious symptoms until it's too late.
The experts also found those on the drugs were 30 per cent less likely to die during the study period.
The team saw even bigger benefits in people over 60, women, and those with a body mass index between 30 and 40.
There was no difference in the chances of Parkinson's disease or brain bleeds between the groups.
The academics said their findings suggest "potential neuroprotective and cerebrovascular benefits" of the drugs but they called for more studies to confirm the research.
"These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity," they wrote.
Commenting on the study, Professor Tara Spires-Jones, from the University of Edinburgh, said: "This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity.
"This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain.
"It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions.
"Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity."
'This is a really exciting '
Dr Richard Oakley, from the Alzheimer's Society, said: "It is well established that diabetes and obesity can increase your risk of developing dementia.
"This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity.
"Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear.
"There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia."
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
Scientists discover new link between Mounjaro and BREAST cancer
Mounjaro could help slash the risk of breast cancer tumours developing, exciting new research has suggested. The game-changing weight loss jabs have ushered in a new era in the war on obesity, but have also been linked to other health benefits, such as reducing the risk of heart attacks, strokes and kidney disease. Now, scientists have discovered that tirzepatide—the ingredient behind Mounjaro—may 'significantly' slow the growth of breast cancer tumours. American scientists, who carried out the trial, said the findings on mice show the drugs have a 'beneficial impact' on women with the disease. However, they cautioned further research was necessary to confirm their findings. Researchers also didn't speculate why the drug, which belong to class of medications called GLP-1 agonists, might lower a patient's chances of cancer. It comes as breakthrough research in May revealed that GLP-1s could help ward off up to 14 types of cancer including breast. Studies have also suggested obesity is a major risk factor in breast cancer returning and weight loss could improve outcomes. The game-changing weight loss jabs have ushered in a new era in the war on obesity, but have also been linked to other health benefits, such as slashing the risk of heart attacks, strokes and kidney disease Amanda Kucinskas, a research fellow in obesity and breast cancer risk at the University of Michigan and study author, said: 'While it is very preliminary data, our studies in mice suggest that these new anti-obesity drugs may be a way to reduce obesity-associated breast cancer risk or improve outcomes. 'While these are very preliminary results, they suggest that this new anti-obesity drug may also have a beneficial impact on breast cancer outcomes,' In the study, researchers tracked 16 nine-week-old mice with breast cancer tumours who were fed a high-fat diet to induce obesity. At 32 weeks old—roughly middle age for a mouse—the obese animals were divided into two groups. One group received tirzepatide injections every other day for 16 weeks, and the other a placebo. Scientists then measured the mice's weight and tumour growth twice a week. They found mice on the medication lost around a fifth of their body weight—roughly the average weight lost by patients taking Mounjaro long term. The fat loss occurred mainly in adipose tissue, the body's fat-storing cells. Mice treated with tirzepatide also had significantly smaller tumors, the scientists said. There was a 'clear link' between lower body weight and smaller tumor size, while total fat mass was also 'strongly linked' to how large the tumors became, they added. However, they cautioned that exactly how tirzepatide slowed tumour growth was not yet understood and further tests, including in humans, would first be necessary. The findings were presented in full this week at ENDO 2025, the Endocrine Society's annual meeting in San Francisco. It comes as research presented at the American Society for Clinical Oncology (ASCO) annual conference in May suggested GLP-1s could slash the risk of 14 obesity-related cancer—including breast—for people with diabetes. US scientists found those on GLP-1s had a 7 per cent lower risk of developing an obesity-related cancer than patients on DDP-4 inhibitors, another diabetes medication. When other health benefits were factored in, these patients were also 8 per cent less likely to die over the 10-year period. In December, groundbreaking research presented at the San Antonio Breast Cancer Symposium also suggested the jabs could also help protect against breast cancer returning. One study of more than 1,000 patients by the University of Texas found obese patients who took the drugs for just over a year after finishing treatment on average had a 'significantly improved' chance of living longer. However, surprisingly, they also found patients taking hormone drugs such as tamoxifen—given to many women to stop breast cancer recurrence—gained weight, despite using the jabs. At the time, experts told MailOnline they were unsure why this happened. But they suggested it may be because hormone therapy typically causes patients to gain weight, meaning the jabs aren't able to work effectively. For these patients, 'we may need to go up to a higher dose', Professor Neil Iyengar, then an oncologist at the Memorial Sloan Kettering Cancer Centre, New York, said.
Reuters
an hour ago
- Reuters
Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says
HYDERABAD, July 16 (Reuters) - Biocon ( opens new tab aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, seeking to tap into a market that is estimated to grow to $150 billion globally by the early 2030s. The push comes after Danish drugmaker Novo Nordisk ( opens new tab and U.S.-based rival Eli Lilly (LLY.N), opens new tab saw skyrocketing demand for their obesity drugs Wegovy and Zepbound. Biopharmaceutical company Biocon plans to submit a request for approval to India's drug regulator by the end of 2026 and potentially launch in 2027 through a partner, CEO Siddharth Mittal said in an email interview on Tuesday. The company, which also makes insulin products, expects to complete late-stage trials within the next 12 to 18 months, he added. "Biocon is actively progressing with filings for semaglutide in Canada as well as many other emerging markets," Mittal said. Semaglutide is the active ingredient in Novo's drugs Ozempic and Wegovy, used for diabetes and weight-loss management. Indian generic drugmakers, including Dr Reddy's ( opens new tab and Cipla ( opens new tab, have been racing to produce cheaper versions of Wegovy when semaglutide goes off patent in 2026. Novo launched Wegovy in India for diabetes and weight-loss management in June after Lilly's Mounjaro sales doubled within a few months following its launch in the south Asian country. Biocon plans to file with Canadian regulatory authorities this quarter for generic versions of Ozempic and later this year for Wegovy versions. "Subject to approval, we could look at a market launch in late 2026 or early 2027," he said. Canada has not approved any such therapies yet, the company said. In addition to Canada, Biocon will focus on large emerging markets such as Brazil and Mexico in Latin America, Malaysia and Hong Kong, countries in the Middle East, as well as Australia, and New Zealand to launch obesity drugs, according to the CEO. In markets where Biocon does not have a direct presence, it is seeking local partnerships to commercialise its products, Mittal said.
Medical News Today
2 hours ago
- Medical News Today
Gabapentin users may face 85% higher cognitive impairment risk
Gabapentin is a medication that, in the United States, is approved to treat seizures and shingles-related neuralgia. It is also used off-label to treat other health issues, including low back pain. Past studies have also found that using gabapentin may increase a person's risk of developing cognitive impairment and dementia. A new study reports that people who receive six or more prescriptions of gabapentin for lower back pain are at a higher risk of developing dementia and mild cognitive found these risks were more than doubled in adults between the ages of 35 to 49 is a medication that is approved by the Food and Drug Administration (FDA) for the treatment of some epileptic seizures, moderate-to-severe restless legs syndrome, and postherpetic neuralgia, which is a nerve pain associated with shingles. Additionally, gabapentin is sometimes prescribed off-label for anxiety disorders, insomnia, hot flashes, alcohol use disorder, akathisia, diabetic peripheral neuropathy, and lower back pain. Like all medications, gabapentin has some potential side effects, including dizziness, tiredness, water retention, and dry mouth. Past studies have also found that using gabapentin may cause breathing difficulties, and may increase a person's risk of developing cognitive impairment and dementia. Now, a new study published in the journal Regional Anesthesia & Pain Medicine reports that people who receive six or more prescriptions of gabapentin for lower back pain are at a higher risk of developing dementia and mild cognitive impairment (MCI). Scientists also discovered these risks were more than doubled in adults between the ages of 35 to 49 How does it affect dementia, MCI risk?For this study, researchers analyzed data from more than 26,000 adults through the federated health research network selected participants who had a diagnosis of chronic pain, chronic pain syndrome, lumbar radiculopathy, and chronic low back pain. They also categorized study participants into different age groups: 18–64, 18–34, 35–49, 50–64, and 65 or older. Researchers assess 10-year outcomes on study participants to see what percentage developed dementia, generally, or specifically Alzheimer's disease, vascular dementia, or MCI. 'Currently, there is a discrepancy on whether taking gabapentin increases a patient's risk for developing dementia,' Nafis B. Eghrari, a 4th-year medical student at Case Western Reserve University School of Medicine in Cleveland, OH, and first author of this study, told Medical News Today.'Moreover, there lacks a strong understanding of how gabapentin impacts cognitive function and whether it contributes to neurodegenerative processes. Previous studies have shown mixed findings on this topic. Thus, we decided to explore this gap in the field,' explained Eghrari.6 or more gabapentin prescriptions linked to 85% higher MCI riskUpon analysis, researchers found that study participants who received six or more gabapentin prescriptions had a 29% higher risk of developing dementia, and an 85% greater chance of being diagnosed with MCI.'The significance of this finding is an association between gabapentin prescription and dementia on a nationwide level,' Eghrari explained. 'Though this does not imply causation, this warrants further investigation on the drug's long-term effects.''In terms of clinical significance, I recommend that physicians prescribing gabapentin for chronic pain perform cognitive exams on a regular basis when seeing patients,' he continued.'I'd also advise patients who are taking this drug to alert their physician if they notice any cognitive deficits, including confusion, poor memory, or slowed thinking,' said the doubled in 35–49-year-oldsEghrari and his team also discovered that when looking at participants by age groups, the risks for dementia more than doubled and more than tripled for MCI in people who were 35 to 49 years old. 'We were surprised to find this relatively higher risk in the non-elderly population,' Eghrari said.'These results indicate that gabapentin may have a greater cognitive impact on non-elderly individuals, as elderly individuals are already at risk for neurodegeneration due to their older age. This finding warrants further investigation into the underlying mechanism of how gabapentin may impact cognition.' – Nafis B. Eghrari'The key takeaway of this study is that patients prescribed gabapentin for chronic back pain should be closely monitored by their physician for cognitive decline,' he continued. 'Moreover, gabapentin should be prescribed with caution due to the associated risk of dementia/cognitive impairment.''We hope to carry this research forward and explore whether there is a true causative relationship between gabapentin and cognitive impairment,' Eghrari added. 'We also plan to investigate the underlying mechanisms of how the drug may impact cognition.'What are the drawbacks of large dataset studies?MNT had the opportunity to speak with Neel Anand, MD, MCh Orth, a board-certified orthopedic spine surgeon and director of the Cedars-Sinai Spine Center in Los Angeles, about this study. Anand, who was not involved in the research, commented that there are pros and cons to studies with big data sets as there are many variables and it is hard to determine the true causative little or no information was provided on any other illnesses participants may have had or other medications they were taking.'The best thing I would take from the study is […] [that] there's not a single drug without a side effect — they all have some issues,' Anand pointed out. 'So the answer is, if you're chronically going to take something, you better watch out — something's [potentially] going to go wrong somewhere.'Anand said the best way to prove anything is to take a cohort of study participants who take a specific medication and nothing else, and compare them to another cohort who does not take the medication. And researchers need to ensure that participants take the medication if it is prescribed to noted that, in some cases, patients do not follow the doctor's indications regarding prescription medication. 'Sometimes they do more, sometimes they'll take less,' Anand said. 'The only way to actually study [the real-life effects of long-term drug use] would be to literally take a thousand people and give them gabapentin and nothing else, and a thousand you don't, and then follow them over 5 years or more,' he he admitted that 'at least we can be cognizant' that there may be a heightened risk of dementia with prolonged gabapentin is 'a possibility that [doctors] needs to be aware [of] or at least counsel our patients [on] — that's fair,' Anand added.
